The disease gradually takes away the skills children have learned—leading to seizures, movement difficulties and profound ...

Spruce Biosciences Receives U.S. FDA Breakthrough Therapy Designation for Tralesinidase Alfa Enzyme Replacement Therapy (TA-ERT) in Sanfilippo Syndrome Type B (MPS IIIB) Breakthrough Therapy ...

Denali Therapeutics faces an FDA review delay for its Hunter syndrome drug, pushing potential approval of tividenofusp alfa to April 2026.

Ultragenyx (RARE) stock is down 40% since March 2024 amid ongoing financial struggles. See more insights on its growth ...

President Donald Trump’s first term championed a vision of American healthcare rooted in innovation, patient choice, and ...

Shares of Spruce Biosciences were lower after the company said it had agreed to sell shares in a private placement expected to raise $50 million in gross proceeds. The stock fell 23% to $140 in ...

The microcap biotech stock had its best day ever after the FDA granted its rare-disease drug a breakthrough designation.

The biotech company is working on a treatment for Sanfilippo syndrome type B, a rare and genetic disorder that affects the brain and the nervous system. Please watch the video at Investors.com - These ...

Spruce Biosciences, Inc. (Nasdaq: SPRB), a late-stage biopharmaceutical company focused on developing and commercializing novel therapies for neurological disorders with significant unmet medical need ...

Pharmaceutical stock Hyperion DeFi Inc (NASDAQ:HYPD) is one of the worst stocks on the Nasdaq today, down 15.9% to trade at $8.74 at last glance. Though the reason for today's price action is unclear, ...

JCR Pharmaceuticals Co., Ltd. (TSE 4552; “JCR”), a global specialty biopharmaceutical company dedicated to developing therapies for rare and genetic diseases, today announced an exclusive licensing ...

Detailed price information for Spruce Biosciences Inc (SPRB-Q) from The Globe and Mail including charting and trades.